Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Peter Crooks to Administration, Cutaneous

This is a "connection" page, showing publications Peter Crooks has written about Administration, Cutaneous.

 
Connection Strength
  
 
 
0.382
  
  1. Eldridge JA, Milewski M, Stinchcomb AL, Crooks PA. Synthesis and in vitro stability of amino acid prodrugs of 6-?-naltrexol for microneedle-enhanced transdermal delivery. Bioorg Med Chem Lett. 2014 Nov 15; 24(22):5212-5.
    View in: PubMed
    Score: 0.126
  2. Yerramreddy TR, Milewski M, Penthala NR, Stinchcomb AL, Crooks PA. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery. Bioorg Med Chem Lett. 2010 Jun 01; 20(11):3280-3.
    View in: PubMed
    Score: 0.092
  3. Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci. 2010 Jul; 99(7):3072-80.
    View in: PubMed
    Score: 0.023
  4. Kiptoo PK, Paudel KS, Hammell DC, Pinninti RR, Chen J, Crooks PA, Stinchcomb AL. Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. J Pharm Sci. 2009 Feb; 98(2):583-94.
    View in: PubMed
    Score: 0.021
  5. Kiptoo PK, Paudel KS, Hammell DC, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci. 2008 Apr 23; 33(4-5):371-9.
    View in: PubMed
    Score: 0.020
  6. Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. J Control Release. 2006 Jun 28; 113(2):137-45.
    View in: PubMed
    Score: 0.018
  7. Nalluri BN, Milligan C, Chen J, Crooks PA, Stinchcomb AL. In vitro release studies on matrix type transdermal drug delivery systems of naltrexone and its acetyl prodrug. Drug Dev Ind Pharm. 2005 Oct; 31(9):871-7.
    View in: PubMed
    Score: 0.017
  8. Paudel KS, Nalluri BN, Hammell DC, Valiveti S, Kiptoo P, Hamad MO, Crooks PA, Stinchcomb AL. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. J Pharm Sci. 2005 Sep; 94(9):1965-75.
    View in: PubMed
    Score: 0.017
  9. Valiveti S, Paudel KS, Hammell DC, Hamad MO, Chen J, Crooks PA, Stinchcomb AL. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. Pharm Res. 2005 Jun; 22(6):981-9.
    View in: PubMed
    Score: 0.017
  10. Valiveti S, Hammell DC, Paudel KS, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. J Control Release. 2005 Feb 02; 102(2):509-20.
    View in: PubMed
    Score: 0.016
  11. Hammell DC, Hamad M, Vaddi HK, Crooks PA, Stinchcomb AL. A duplex "Gemini" prodrug of naltrexone for transdermal delivery. J Control Release. 2004 Jun 18; 97(2):283-90.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.